The xT CDx is a sophisticated Next Generation Sequencing (NGS)-based diagnostic device aimed specifically at identifying genetic alterations in solid tumors. It encompasses a wide range of detection capabilities including single nucleotide variants, insertions, deletions, and microsatellite instability status across 648 genes. Designed to provide targeted treatment paths, the xT CDx plays a critical role in precision oncology by aligning with therapeutic product labels for companion diagnostics. By leveraging both tumor and matched normal samples, this device's comprehensive approach ensures nuanced insights into tumor biology, enabling more personalized therapy regimens for patients. In addition to cancer profiling, xT CDx enhances the accuracy of somatic alteration identification by utilizing a tumor + normal match methodology, minimizing false positives and improving therapy targeting efficiencies. Through its advanced NGS platform, xT CDx is integral to Tempus Labs' drive to enhance personalized cancer care.
